Leukemia-specific allogeneic donor T cells: quantification by limiting dilution assay.
Allogeneic T cells are capable of discriminating between leukemia cells and non-malignant hematopoetic cells. This has been concluded from clinical BMT data and demonstrated by in vitro experiments. We analyzed the frequency and specificity of leukemia-reactive T cells from syngeneic and allogeneic blood donors by limiting dilution assays for interleukin-2-producing (TH1) and cytotoxic (CTLp) T cells. Target cells were leukemia blasts obtained from a patient with common ALL. Control targets were generated by EBV transformation. Effector cells were generated from the peripheral blood of the patient in remission, from his syngeneic brother and from eight healthy, HLA-mismatched volunteers. The effector cells were stimulated with leukemia cells and interleukin-2. Neither the patient nor his brother were able to generate anti-leukemic CTLp or TH1. The HLA-mismatched allogeneic donors displayed anti-leukemic CTLp frequencies with a range from 0 to 68 million. TH1 cells with anti-leukemic specificity were not detectable. We conclude that there are great inter-individual differences in the GVL potential of fully allogeneic peripheral T lymphocytes. It is possible to identify T cell lines with reactivity against leukemia blasts and non-reactivity against normal hematological cells from the same individual. These cell lines are potential effector cells for immunotherapy of human leukemia.
Salomo
M
M
Institute of Immunology, University of Kiel, Germany.
Steinmann
J
J
Glass
B
B
Herwartz
C
C
Uharek
L
L
Gassmann
W
W
Müller-Ruchholtz
W
W
D001782:Blood Donors; D003602:Cytotoxicity, Immunologic; D006650:Histocompatibility Testing; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis / Q000276:immunology; D007938:Leukemia / Q000276:immunology* / Q000473:pathology; D008285:Major Histocompatibility Complex / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*
D007376:Interleukin-2